ES2082132T3 - Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos. - Google Patents

Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.

Info

Publication number
ES2082132T3
ES2082132T3 ES91302404T ES91302404T ES2082132T3 ES 2082132 T3 ES2082132 T3 ES 2082132T3 ES 91302404 T ES91302404 T ES 91302404T ES 91302404 T ES91302404 T ES 91302404T ES 2082132 T3 ES2082132 T3 ES 2082132T3
Authority
ES
Spain
Prior art keywords
antibody
fragments
composition containing
different antibodies
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91302404T
Other languages
English (en)
Inventor
Thomas Stewart Beggs
Paul James Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever NV
Original Assignee
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296814&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2082132(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909006327A external-priority patent/GB9006327D0/en
Priority claimed from GB909021671A external-priority patent/GB9021671D0/en
Application filed by Unilever NV filed Critical Unilever NV
Application granted granted Critical
Publication of ES2082132T3 publication Critical patent/ES2082132T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/94—Involves covalent bonding to the substrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

UNO O MAS COSMETICOS O VEHICULOS ACEPTADOS FARMACEUTICAMENTE (POR EJ. UNA PASTA DENTIFRICA O ENJUAGADOR BUCAL) CONTIENEN UN ANTICUERPO O FRAGMENTO DE ANTICUERPO QUE SE UNE A UN OBJETIVO, ADEMAS DE UNO O DOS ANTICUERPOS O FRAGMENTO DE ANTICUERPOS MAS QUE COLECTIVAMENTE SON CAPACES DE UNIR EL AGENTE AL PRIMER ANTICUERPO. EN SU USO, LA UNION INMUNOLOGICA UNE EL AGENTE AL OBJETIVO Y NO SE NECESITA UNA CONJUGACION QUIMICA. EN UN SISTEMA PREFERENTE SE UNEN DOS ENZIMAS DE COPERACION EN PROXIMIDAD CERCANA .
ES91302404T 1990-03-21 1991-03-20 Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos. Expired - Lifetime ES2082132T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909006327A GB9006327D0 (en) 1990-03-21 1990-03-21 Delivery of therapeutic agents
GB909021671A GB9021671D0 (en) 1990-10-05 1990-10-05 Delivery of agents

Publications (1)

Publication Number Publication Date
ES2082132T3 true ES2082132T3 (es) 1996-03-16

Family

ID=26296814

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91302404T Expired - Lifetime ES2082132T3 (es) 1990-03-21 1991-03-20 Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.

Country Status (9)

Country Link
EP (1) EP0453097B1 (es)
JP (1) JP3098050B2 (es)
AT (1) ATE131069T1 (es)
AU (1) AU641736B2 (es)
BR (1) BR9101117A (es)
CA (1) CA2038578C (es)
DE (1) DE69115104T2 (es)
ES (1) ES2082132T3 (es)
IN (1) IN172885B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1009834C2 (nl) * 1998-08-10 2000-02-11 Stanislaus Laurens Johan Woute Antistoffen voor toepassing in de gerichte en tijdelijke behandeling van mens en dier.
AU7648900A (en) * 1999-09-16 2001-04-17 Unilever Plc Delivery system for antidandruff agent
US7220405B2 (en) 2003-09-08 2007-05-22 E. I. Du Pont De Nemours And Company Peptide-based conditioners and colorants for hair, skin, and nails
US7285264B2 (en) 2003-09-08 2007-10-23 E.I. Du Pont De Nemours And Company Peptide-based body surface coloring reagents
US7807141B2 (en) 2003-09-08 2010-10-05 E.I. Du Pont De Nemours And Company Peptide-based oral care surface reagents for personal care
US7585495B2 (en) 2003-09-08 2009-09-08 E. I. Du Pont De Nemours And Company Method for identifying shampoo-resistant hair-binding peptides and hair benefit agents therefrom
US7736633B2 (en) 2005-09-28 2010-06-15 E.I. Du Pont De Nemours And Company Method for enhancing effects of colorants and conditioners
US9636196B2 (en) 2008-06-13 2017-05-02 ProBiora Health, LLC Use of hydrogen peroxide-producing bacteria for tooth whitening
WO2010114638A1 (en) 2009-03-30 2010-10-07 E. I. Du Pont De Nemours And Company Peptide-based tooth whitening reagents
ES2784495T3 (es) 2010-12-20 2020-09-28 Dupont Us Holding Llc Generación enzimática de perácidos para su uso en productos para el cuidado bucodental

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433593A (en) * 1972-06-09 1976-04-28 Royal College Of Surgeons Conjugates
DD249977A1 (de) * 1986-06-10 1987-09-23 Magdeburg Medizinische Akad Verfahren zur qualitativen oder quantitativen bestimmung von str. b iii oder 1a str. b iii
IL83567A (en) * 1986-08-18 1992-02-16 Dow Chemical Co Starburst conjugates with a carried material,such as an agricultural or pharmaceutical material
US4943525A (en) * 1987-11-02 1990-07-24 Bioventures, Inc. Simultaneous immunoassay for the determination of antigens and antibodies
SE461570B (sv) * 1988-06-06 1990-03-05 Rama Bio Link Ab Farmaceutiskt preparat och konjugat av en baktericid och en antikropp
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics
WO1991000112A1 (en) * 1989-06-30 1991-01-10 Brunswick Corporation Antibody-lactate oxidase conjugates

Also Published As

Publication number Publication date
BR9101117A (pt) 1991-11-05
CA2038578C (en) 2000-11-21
DE69115104D1 (de) 1996-01-18
AU7299591A (en) 1991-10-03
EP0453097A2 (en) 1991-10-23
EP0453097B1 (en) 1995-12-06
JPH05262669A (ja) 1993-10-12
AU641736B2 (en) 1993-09-30
CA2038578A1 (en) 1991-09-22
ATE131069T1 (de) 1995-12-15
JP3098050B2 (ja) 2000-10-10
EP0453097A3 (en) 1991-10-30
DE69115104T2 (de) 1996-05-15
IN172885B (es) 1993-12-25

Similar Documents

Publication Publication Date Title
NO984136L (no) Humanisert kimµrt antistoffmolekyl for bruk som dianostikum, og diagnostisk preparat omfattende et slikt antistoffmolekyl
EP1378525A3 (en) Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
CA2128511A1 (en) Monomeric and dimeric antibody-fragment fusion proteins
DE69729283D1 (de) GLYKOSYLIERTE IgG ANTIKÖRPER
EE05496B1 (et) Antikeha, mis seob osteoprotegeriini siduvat valku
EP1808155A3 (en) Antibody-serum protein hybrids
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
GB2278357B (en) Humanised antibodies directed against A33 antigen
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
ES2088464T3 (es) Uso y administracion de enzimas.
YU46858B (sh) Postupak za dobijanje imunoglobulinskih konjugata
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
AU1094999A (en) Monoclonal antibody to alpha2-macroglobulin and its use for detecting glucan
FI956041A (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
BR9810574A (pt) Anticorpo monoclonal, fragmento de anticorpo, mistura ou derivado destes, uso dos mesmos, célula, e, preparação farmacêutica.
IL80918A (en) Monoclonal antibodies cross-reactive and cross-protective against p.aeruginosa serotypes and pharmaceutical compositions and kits containing said antibodies
NO882518D0 (no) Fremgangsmaater ved forbedret binding til antistoff, antistoff-fragmenter, hormoner og andre bindingsmidler, og konjugater derav.
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 453097

Country of ref document: ES